2020-2027 Analysis and Review Sucralfate Chewable Tablets Market

Sucralfate Chewable Tablets Market

Sucralfate Chewable Tablets Market By Indication (Duodenal Ulcers and Gastroesophageal Reflux Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

05-03-2020 REP-HC-5045 40 Tables 122 pages Format

The sucralfate chewable tablets market was valued at USD219.3Mn by 2019. As per the latest research citings brought forward by the World Health Organization (WHO), approximately 4.4 billion people worldwide have been infected with H.pylori infection during their lifetime causing severe abdominal pain. Growing trend for consumption of spicy food and frequent intake of NSAID’s for pain management concomitantly drive the sucralfate chewable tablets market growth.

 Sucralfate Chewable Tablets Market

Sucralfate is a locally acting substance which forms a viscous, cross-linking, paste-like material in an acidic environment of the stomach which attaches to the protein present on the surface of the gastric mucosa. It reacts with fibrinogen and albumin to form an insoluble complex which protects the ulcer and eroded surface from further exposure to gastric acid.

The major segments related to the sucralfate chewable tablets market are:

By Indication (2017–2027; US$ Mn)

Duodenal Ulcers

Gastro Esophageal Reflux Disease

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global sucralfate chewable tablets market
  • The overall segmentation of the sucralfate chewable tablets market, by indication, distribution channel, and geography is minutely studied. Duodenal ulcers and hospital pharmacy are dominating the indication and distribution channel segments respectively
  • Rising prevalence of helicobacter pylori-associated duodenal ulcers and increasing demand for spicy food together drive the sucralfate chewable tablets market
  • Availability of low-cost generic versions of sucralfate chewable tablets further propels its market growth

Report gist?

  • The study of the global sucralfate chewable tablets market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of indication and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in manufacturing and marketing of sucralfate chewable tablets which are gaining huge demand owing to rising prevalence of duodenal ulcers and a significant rise in the consumption of spicy food worldwide
  • The report will benefit gastroenterologist to prescribe sucralfate chewable tablets to patients suffering from GERD
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to sucralfate chewable tablets market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Duodenal ulcers are reigning the indication segment for sucralfate chewable tablets market. The chief causative agent for the disease prognosis of duodenal ulcers in the H.pylori infection. Injudicious intake of non-steroidal anti-inflammatory drugs on regular occasions is also related to the occurrence of duodenal ulcers. Gastroesophageal reflux disease is going to register excellent market growth in the near future owing to the growing attraction for spicy food, chocolates, and pregnancy. Additionally, a significant rise in smoking, alcohol consumption, and obesity are strong indicators for the onset of gastroesophageal reflux disease in the adult population ranging from 30 to 39 years.

In the present scenario hospital pharmacy is leading the distribution channel segment for sucralfate chewable tablets market. The chief causative agent is the constant rise in the number of patients visiting physician’s clinics to seek prescription of sucralfate chewable tablets for the treatment of duodenal ulcer and gastroesophageal reflux disease. Retail pharmacy is going to be the fastest-growing segment in the near future on account of the availability of low-cost generic versions of sucralfate chewable tablets and the capacity to serve communities residing in remote locations.

North America is spearheading the geography segment for sucralfate chewable tablets market. The prime feature which increases its market growth is the rising prevalence of duodenal ulcers in the region. According to the latest research citings provided by the Center for Disease Control and Prevention (CDC), approximately 4.6 million people in the United States are reported to be suffering from duodenal ulcers annually. The causative agents associated with the duodenal ulcers in North America are H.pylori infection and drug-associated hyperacidity causing stomach mucosal erosion. Furthermore affordable reimbursement scenarios associated with the sucralfate chewable tablets prescribed as a cytoprotective agent. Europe is holding the second largest regional market for the sucralfate chewable tablets chiefly due to the rising prevalence of gastroesophageal reflux disease in the adult population. According to the European Commission report the prevalence rate of GERD in the European region is 2.5% to 7.8%. High consumption of chocolates and constant rise in obesity together determine the sucralfate chewable tablets market growth in the region. Asia Pacific is set to register impressive market growth during the forecast period owing to the rising prevalence of gastrointestinal disorder on account of increasing consumption of spices in daily dietary intake and flourishing generic drugs market.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.